Plasmon-Driven Catalytic Chemotherapy Augments Cancer Immunotherapy through Induction of Immunogenic Cell Death and Blockage of IDO Pathway

Plasmon-Driven Catalytic Chemotherapy Augments Cancer Immunotherapy through Induction of Immunogenic Cell Death and Blockage of IDO Pathway

© 2021 Wiley-VCH GmbH.

Bibliographische Detailangaben
Veröffentlicht in:Advanced materials (Deerfield Beach, Fla.). - 1998. - 33(2021), 34 vom: 05. Aug., Seite e2102188
1. Verfasser: Ding, Yuan (VerfasserIn)
Weitere Verfasser: Sun, Zhongquan, Gao, Yong, Zhang, Sitong, Yang, Caixia, Qian, Zhefeng, Jin, Lulu, Zhang, Jiaojiao, Zeng, Cheng, Mao, Zhengwei, Wang, Weilin
Format: Online-Aufsatz
Sprache:English
Veröffentlicht: 2021
Zugriff auf das übergeordnete Werk:Advanced materials (Deerfield Beach, Fla.)
Schlagworte:Journal Article 'immunogenic cell death drug delivery immunotherapy plasmon-driven catalysis stimuli-activation Antineoplastic Agents Drug Carriers Enzyme Inhibitors Immunosuppressive Agents Indoleamine-Pyrrole 2,3,-Dioxygenase
LEADER 01000naa a22002652 4500
001 NLM328239771
003 DE-627
005 20231225202534.0
007 cr uuu---uuuuu
008 231225s2021 xx |||||o 00| ||eng c
024 7 |a 10.1002/adma.202102188  |2 doi 
028 5 2 |a pubmed24n1094.xml 
035 |a (DE-627)NLM328239771 
035 |a (NLM)34278622 
040 |a DE-627  |b ger  |c DE-627  |e rakwb 
041 |a eng 
100 1 |a Ding, Yuan  |e verfasserin  |4 aut 
245 1 0 |a Plasmon-Driven Catalytic Chemotherapy Augments Cancer Immunotherapy through Induction of Immunogenic Cell Death and Blockage of IDO Pathway 
264 1 |c 2021 
336 |a Text  |b txt  |2 rdacontent 
337 |a ƒaComputermedien  |b c  |2 rdamedia 
338 |a ƒa Online-Ressource  |b cr  |2 rdacarrier 
500 |a Date Completed 18.01.2022 
500 |a Date Revised 18.01.2022 
500 |a published: Print-Electronic 
500 |a Citation Status MEDLINE 
520 |a © 2021 Wiley-VCH GmbH. 
520 |a Clinical trials confirm the combination of indoleamine 2,3-dioxygenase (IDO) blockade and immunogenic chemotherapy represents a brilliant future in cancer therapy. However, it remains challenging to precisely activate chemo-immunotherapy in situ to avoid side effects from the systemic administrations and reverse the poor immunogenicity and immunosuppressive microenvironment in tumor sites. Herein, a hybrid nanomedicine ("RPMANB NPs") to co-deliver an IDO inhibitor (NLG919) and a chemotherapeutic prodrug to amplify the therapeutic benefits are designed. Attributed to the delicate surface engineering, the RPMANB NPs possess excellent pharmacokinetics and tumor accumulation. The loaded NLG919 are released inside cancer tissues/cells due to the collapse of the metal-organic framework platform triggered by the highly concentrated phosphate, reversing the immunosuppressive tumor microenvironment by suppressing IDO activity. The potent chemotherapeutic drug is precisely activated through a highly efficient plasmon-driven catalysis in the presence of near-infrared light, eliciting antitumor immunity by triggering immunogenic cell death and avoiding side effects through in situ activation of chemotherapy. In vivo studies demonstrate that the chemo-immunotherapy greatly suppresses the tumor growth by promoting intratumoral accumulation of cytotoxic T lymphocytes and downregulating regulatory T cells. This work establishes a robust delivery platform to overcome the current obstacles of tumor treatments by combining precisely activatable chemotherapy with immunotherapy 
650 4 |a Journal Article 
650 4 |a 'immunogenic cell death 
650 4 |a drug delivery 
650 4 |a immunotherapy 
650 4 |a plasmon-driven catalysis 
650 4 |a stimuli-activation 
650 7 |a Antineoplastic Agents  |2 NLM 
650 7 |a Drug Carriers  |2 NLM 
650 7 |a Enzyme Inhibitors  |2 NLM 
650 7 |a Immunosuppressive Agents  |2 NLM 
650 7 |a Indoleamine-Pyrrole 2,3,-Dioxygenase  |2 NLM 
700 1 |a Sun, Zhongquan  |e verfasserin  |4 aut 
700 1 |a Gao, Yong  |e verfasserin  |4 aut 
700 1 |a Zhang, Sitong  |e verfasserin  |4 aut 
700 1 |a Yang, Caixia  |e verfasserin  |4 aut 
700 1 |a Qian, Zhefeng  |e verfasserin  |4 aut 
700 1 |a Jin, Lulu  |e verfasserin  |4 aut 
700 1 |a Zhang, Jiaojiao  |e verfasserin  |4 aut 
700 1 |a Zeng, Cheng  |e verfasserin  |4 aut 
700 1 |a Mao, Zhengwei  |e verfasserin  |4 aut 
700 1 |a Wang, Weilin  |e verfasserin  |4 aut 
773 0 8 |i Enthalten in  |t Advanced materials (Deerfield Beach, Fla.)  |d 1998  |g 33(2021), 34 vom: 05. Aug., Seite e2102188  |w (DE-627)NLM098206397  |x 1521-4095  |7 nnns 
773 1 8 |g volume:33  |g year:2021  |g number:34  |g day:05  |g month:08  |g pages:e2102188 
856 4 0 |u http://dx.doi.org/10.1002/adma.202102188  |3 Volltext 
912 |a GBV_USEFLAG_A 
912 |a SYSFLAG_A 
912 |a GBV_NLM 
912 |a GBV_ILN_350 
951 |a AR 
952 |d 33  |j 2021  |e 34  |b 05  |c 08  |h e2102188